Literature DB >> 1883816

Antisense inhibition of ras p21 expression that is sensitive to a point mutation.

E H Chang1, P S Miller, C Cushman, K Devadas, K F Pirollo, P O Ts'o, Z P Yu.   

Abstract

Many genetic disorders result from a single point mutation, and many tumor oncogenes have been found to be altered by a point mutation. The ability to inhibit selectively the expression of the mutated form of a protein without affecting its normal counterpart is central to many therapeutic strategies, since the normal protein may serve indispensable functions. Antisense oligonucleoside methylphosphonates and their psoralen derivatives directed at either normal human Ha-ras p21 or ras p21 that is mutated at a single base in codon 61 have been examined for their efficacy and specificity as inhibitors of p21 expression. Mixed cultures of cells expressing both forms of p21 were treated with the antisense oligomer complementary to the normal p21 or with the antisense oligomer complementary to the point-mutated p21. Each of the antisense oligomers specifically inhibited expression of only the form of ras p21 to which it was completely complementary and left the other form of p21 virtually unaffected.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1883816     DOI: 10.1021/bi00098a001

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

Review 1.  Gene therapy in lung cancer.

Authors:  S G Swisher; J A Roth
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

Review 2.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures.

Authors:  R V Giles; D M Tidd
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

4.  Specificity of antisense oligonucleotides in vivo.

Authors:  T M Woolf; D A Melton; C G Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

5.  Effect of a neutralized phosphate backbone on the minor groove of B-DNA: molecular dynamics simulation studies.

Authors:  Donald Hamelberg; Loren Dean Williams; W David Wilson
Journal:  Nucleic Acids Res       Date:  2002-08-15       Impact factor: 16.971

Review 6.  Oligonucleotide treatment of ras-induced tumors in nude mice.

Authors:  E Wickstrom
Journal:  Mol Biotechnol       Date:  2001-05       Impact factor: 2.695

7.  Antisense properties of duplex- and triplex-forming PNAs.

Authors:  H Knudsen; P E Nielsen
Journal:  Nucleic Acids Res       Date:  1996-02-01       Impact factor: 16.971

Review 8.  DNA and RNA derivatives to optimize distribution and delivery.

Authors:  Eric Wickstrom
Journal:  Adv Drug Deliv Rev       Date:  2015-04-22       Impact factor: 15.470

9.  Hybridization specificity, enzymatic activity and biological (Ha-ras) activity of oligonucleotides containing 2,4-dideoxy-beta-D-erythro-hexopyranosyl nucleosides.

Authors:  K Augustyns; G Godard; C Hendrix; A Van Aerschot; J Rozenski; T Saison-Behmoaras; P Herdewijn
Journal:  Nucleic Acids Res       Date:  1993-10-11       Impact factor: 16.971

10.  Oligonucleotide clamps arrest DNA synthesis on a single-stranded DNA target.

Authors:  C Giovannangeli; N T Thuong; C Hélène
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.